Shareholder Votes

WILLIAMS SONOMA INC shareholders approved Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending January 31, 2027 at the 2026-06-18 meeting.

“On June 18, 2026, Williams-Sonoma, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the following proposals were voted on by the Company’s stockholders: Proposal 1: Election of Board of Directors: Name of Director For Against Abstain Broker Non-Vote Laura Alber 101,258,346 150,110 41,867 7,114,756 Esi Eggleston Bracey 100,800,604 598,295 51,424 7,114,756 Andrew Campion 100,828,231 557,825 64,267 7,114,756 Scott Dahnke 95,821,244 5,569,520 59,559 7,114,756 Anne Finucane 96,608,761 4,791,661 49,901 7,114,756 Arianna Huffington 100,592,969 755,157 102,197 7,114,756 William Ready 78,538,330 22,859,139 52,854 7,114,756 Frits van Paasschen 96,263,913 5,131,473 54,937 7,114,756 All director nominees were duly elected. Proposal 2: Advisory vote to approve executive compensation: For Against Abstain Broker Non-Vote 85,014,187 16,178,546 257,590 7,114,756 Proposal 2 was approved, on a n on-binding advisory basis. Proposal 3: Ratific”

WILLIAMS SONOMA INC shareholders approved Advisory vote to approve executive compensation at the 2026-06-18 meeting.

“On June 18, 2026, Williams-Sonoma, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the following proposals were voted on by the Company’s stockholders: Proposal 1: Election of Board of Directors: Name of Director For Against Abstain Broker Non-Vote Laura Alber 101,258,346 150,110 41,867 7,114,756 Esi Eggleston Bracey 100,800,604 598,295 51,424 7,114,756 Andrew Campion 100,828,231 557,825 64,267 7,114,756 Scott Dahnke 95,821,244 5,569,520 59,559 7,114,756 Anne Finucane 96,608,761 4,791,661 49,901 7,114,756 Arianna Huffington 100,592,969 755,157 102,197 7,114,756 William Ready 78,538,330 22,859,139 52,854 7,114,756 Frits van Paasschen 96,263,913 5,131,473 54,937 7,114,756 All director nominees were duly elected. Proposal 2: Advisory vote to approve executive compensation: For Against Abstain Broker Non-Vote 85,014,187 16,178,546 257,590 7,114,756 Proposal 2 was approved, on a n on-binding advisory basis. Proposal 3: Ratific”

WILLIAMS SONOMA INC shareholders approved Election of Board of Directors at the 2026-06-18 meeting.

“On June 18, 2026, Williams-Sonoma, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the following proposals were voted on by the Company’s stockholders: Proposal 1: Election of Board of Directors: Name of Director For Against Abstain Broker Non-Vote Laura Alber 101,258,346 150,110 41,867 7,114,756 Esi Eggleston Bracey 100,800,604 598,295 51,424 7,114,756 Andrew Campion 100,828,231 557,825 64,267 7,114,756 Scott Dahnke 95,821,244 5,569,520 59,559 7,114,756 Anne Finucane 96,608,761 4,791,661 49,901 7,114,756 Arianna Huffington 100,592,969 755,157 102,197 7,114,756 William Ready 78,538,330 22,859,139 52,854 7,114,756 Frits van Paasschen 96,263,913 5,131,473 54,937 7,114,756 All director nominees were duly elected. Proposal 2: Advisory vote to approve executive compensation: For Against Abstain Broker Non-Vote 85,014,187 16,178,546 257,590 7,114,756 Proposal 2 was approved, on a n on-binding advisory basis. Proposal 3: Ratific”

Akebia Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026 at the 2026-06-17 meeting.

“Proposal 5: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote on Proposal 5 were as follows: Votes For Votes Against Votes Abstaining 173,306,165 15,754,273 2,590,393”

Akebia Therapeutics, Inc. shareholders approved Non-binding advisory recommendation on frequency of future advisory votes on executive compensation at the 2026-06-17 meeting.

“Proposal 4: The Company's stockholders recommended, on a non-binding advisory basis, that future advisory votes on the compensation of the Company's named executive officers be held every year. The results of the non-binding advisory vote on Proposal 4 were as follows: Votes for Every 1 Year Votes for Every 2 Years Votes for Every 3 Years Votes Abstaining 112,927,161 2,739,581 20,605,688 7,080,470”

Akebia Therapeutics, Inc. shareholders approved Non-binding advisory approval of named executive officer compensation at the 2026-06-17 meeting.

“Proposal 3 : The Company's stockholders' approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The results of the non-binding advisory vote on Proposal 3 were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 89,838,833 51,140,010 2,374,057 48,297,931”

Akebia Therapeutics, Inc. shareholders approved Amendment to increase authorized shares of capital stock and common stock at the 2026-06-17 meeting.

“Proposal 2: The Company's stockholders approved an amendment to the Company's Ninth Amended and Restated Certificate of Incorporation to (i) increase the number of authorized shares of capital stock from 375,000,000 to 525,000,000 and (ii) increase the number of authorized shares of common stock, par value $0.00001 per share, from 350,000,000 to 500,000,000 (the “Share Increase Amendment”). The results of the vote on Proposal 2 were as follows: Votes For Votes Against Votes Abstaining 102,504,108 88,853,129 293,594”

Akebia Therapeutics, Inc. shareholders approved Election of Adrian Adams, Michael Rogers and LeAnne M. Zumwalt as Class III directors at the 2026-06-17 meeting.

“Proposal 1: The Company's stockholders elected Adrian Adams, Michael Rogers and LeAnne M. Zumwalt as Class III directors, each to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal. The results of the vote on Proposal 1 were as follows: Votes For Votes Withheld Broker Non-Votes Adrian Adams 102,040,314 41,312,586 48,297,931 Michael Rogers 102,377,117 40,975,783 48,297,931 LeAnne M. Zumwalt 97,926,409 45,426,491 48,297,931”

AdaptHealth Corp. shareholders approved A non-binding advisory vote to approve the compensation paid to the Company's named executive officers at the 2026-06-18 meeting.

“3. Non-binding advisory vote to approve the compensation paid to the Company’s named executive officers. For Against Abstain Broker Non-Vote 107,129,368 965,272 682,032 11,875,821 Based on the votes set forth above, the stockholders approved this proposal on an advisory basis.”

AdaptHealth Corp. shareholders approved To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-18 meeting.

“2. Ratification of Appointment of Independent Registered Public Accounting Firm. For Against Abstain 119,090,024 1,092,126 470,343 Based on the votes set forth above, the stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

AdaptHealth Corp. shareholders approved To elect nine directors for a one-year term at the 2026-06-18 meeting.

“1. Election of Directors. Name For Withheld Broker Non-Vote Gregory Belinfanti 106,611,172 2,165,500 11,875,821 Terence Connors 106,470,008 2,306,664 11,875,821 Brad Coppens 107,111,674 1,664,998 11,875,821 Suzanne Foster 105,992,570 2,784,102 11,875,821 Ted Lundberg 102,690,918 6,085,754 11,875,821 Kenneth A. Samet 108,390,299 386,373 11,875,821 Dr. Susan Weaver 106,714,121 2,062,551 11,875,821 David Williams III 106,543,756 2,232,916 11,875,821 Dale Wolf 105,844,287 2,932,385 11,875,821 Based on the votes set forth above, each director nominee was duly elected”

Crinetics Pharmaceuticals, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers. at the 2026-06-18 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were: Votes For Votes Against Abstentions Broker Non-Votes 91,657,992 2,698,538 2,629,874 5,044,011”

Crinetics Pharmaceuticals, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-18 meeting.

“The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of such vote were: Votes For Votes Against Abstentions 101,675,974 341,727 12,714”

Crinetics Pharmaceuticals, Inc. shareholders approved Election of three Class II directors to the Board of Directors for three-year terms to expire at the 2029 annual meeting of stockholders. at the 2026-06-18 meeting.

“The Company’s stockholders approved the election of three Class II directors to the Board of Directors for three-year terms to expire at the 2029 annual meeting of stockholders. The results of such vote were: Votes For Votes Withheld Broker Non-Votes Caren Deardorf 73,454,076 23,532,328 5,044,011 Weston Nichols, Ph.D. 90,208,564 6,777,840 5,044,011 Stephanie S. Okey, M.S. 72,225,313 24,761,091 5,044,011”

Beyond Air, Inc. shareholders approved Reverse Stock Split Proposal at the 2026-06-18 meeting.

“The voting results were as follows: For Against Abstain Broker Non-Vote 5,177,506 1,222,793 87,461 0 The Reverse Stock Split proposal was approved by the Company’s stockholders.”

INSEEGO CORP. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-16 meeting.

“Proposal 3: Advisory Vote on Executive Compensation The proposal to approve, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers was approved with the following vote: Votes For Votes Against Abstentions Broker Non-Votes 5,322,984 1,245,243 872,743 4,091,791”

INSEEGO CORP. shareholders approved Ratification of Appointment of Independent Registered Public Accountants at the 2026-06-16 meeting.

“Proposal 2: Ratification of Appointment of Independent Registered Public Accountants The proposal to ratify the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accountants for the fiscal year ending December 31, 2026 was approved with the following vote: Votes For Votes Against Abstentions Broker Non-Votes 11,292,499 168,074 72,188 0”

INSEEGO CORP. shareholders approved Election of Directors at the 2026-06-16 meeting.

“Proposal 1: Election of Directors Both of the persons nominated by the Company to serve as directors for a three-year term until the 2029 annual meeting of stockholders were elected with the following votes: Name of Nominee Votes For Votes Withheld Broker Non-Votes James B. Avery 6,714,605 726,365 4,091,791 Jeffrey Tuder 6,331,622 1,109,348 4,091,791”

PagerDuty, Inc. shareholders approved Advisory Vote to Approve Executive Compensation at the 2026-06-18 meeting.

“Proposal 3 — Advisory Vote to Approve Executive Compensation The stockholders approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers. The results of such vote were: For Against Abstain Broker Non-Votes 45,924,468 7,133,053 615,723 12,440,335”

PagerDuty, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-18 meeting.

“Proposal 2 — Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending January 31, 2027. The results of such vote were: For Against Abstain Broker Non-Votes 65,873,998 177,818 61,763 —”

PagerDuty, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.

“Proposal 1 — Election of Directors The stockholders elected each of the four persons named below as Class I directors to serve until the 2029 annual meeting of stockholders or until their successors are elected and qualified. The results of such vote were: For Withheld Broker Non-Votes Donald J. Carty 41,973,771 11,699,473 12,440,335 Sarah Franklin 38,252,555 15,420,689 12,440,335 William Losch 37,425,282 16,247,962 12,440,335 Jennifer Tejada 38,201,630 15,471,614 12,440,335”

National Vision Holdings, Inc. shareholders approved Ratification of appointment of independent registered public accounting firm at the 2026-06-17 meeting.

“Proposal 3: Ratification of the Appointment of the Independent Registered Public Accounting Firm Stockholders ratified the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for fiscal 2026. For Against Abstain 73,341,054 1,913,162 166,011”

National Vision Holdings, Inc. shareholders approved Advisory vote on executive compensation at the 2026-06-17 meeting.

“Proposal 2: Advisory Vote on Executive Compensation Stockholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers. For Against Abstain Broker Non-Vote 70,210,320 2,022,774 136,656 3,050,477”

National Vision Holdings, Inc. shareholders approved Election of eleven director nominees at the 2026-06-17 meeting.

“Proposal 1: Election of Directors Stockholders elected eleven director nominees to hold office for terms expiring at the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified. For Against Abstain Broker Non-Vote Jose Armario 71,479,950 746,786 143,014 3,050,477 L. Reade Fahs 70,773,915 1,427,583 168,252 3,050,477 Virginia A. Hepner 71,450,302 784,077 135,371 3,050,477 Susan Somersille Johnson 71,231,053 1,002,886 135,811 3,050,477 Naomi Kelman 71,595,450 638,489 135,811 3,050,477 James M. McGrann 72,016,968 217,126 135,656 3,050,477 Michael J. Nicholson 71,993,783 239,889 136,078 3,050,477 Susan O’Farrell 71,752,548 481,781 135,421 3,050,477 D. Randolph Peeler 70,794,057 1,406,999 168,694 3,050,477 Alex Wilkes 72,017,052 217,504 135,194 3,050,477 Caitlin Zulla 71,906,943 327,857 134,950 3,050,477”

CrowdStrike Holdings, Inc. shareholders rejected Ratification, on an Advisory Basis, of Supermajority Voting Provisions in Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws at the 2026-06-17 meeting.

“4. Ratification, on an Advisory Basis, of Supermajority Voting Provisions in Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws. The supermajority voting provisions were not ratified, on an advisory basis, based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 24,034,816 144,942,474 1,063,908 39,947,114”

CrowdStrike Holdings, Inc. shareholders approved Approval of an Amendment and Restatement of Our Amended and Restated Certificate of Incorporation to Limit Officer Liability as Permitted by Delaware Law at the 2026-06-17 meeting.

“3. Approval of an Amendment and Restatement of Our Amended and Restated Certificate of Incorporation to Limit Officer Liability as Permitted by Delaware Law. The Amendment and Restatement was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 144,387,962 24,713,003 940,233 39,947,114”

CrowdStrike Holdings, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-06-17 meeting.

“2. Ratification of Selection of Independent Registered Public Accounting Firm. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the Company for the fiscal year ending January 31, 2027 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 207,551,102 1,434,320 1,002,890 N/A”

CrowdStrike Holdings, Inc. shareholders approved Election of Class I Directors to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified at the 2026-06-17 meeting.

“1. Election of Class I Directors. The following nominees were elected to serve as Class I directors until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or, if sooner, until the director’s death, resignation or removal, based on the following results of voting: Nominee Votes For Votes Withheld Broker Non- Votes Johanna Flower 131,014,818 39,026,380 39,947,114 Denis J. O’Leary 104,319,861 65,721,337 39,947,114”

OPAL Fuels Inc. shareholders approved Ratification of the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-17 meeting.

“Proposal 2 - Ratification of the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026. FOR AGAINST ABSTENTIONS Broker Non-Votes 256,881,212 74,151 2,276 —”

OPAL Fuels Inc. shareholders approved Election of eight directors to hold office until the Annual Meeting of Stockholders to be held in 2027 or until each such director’s respective successor is elected and qualified or until each such director’s earlier death, resignation or removal. at the 2026-06-17 meeting.

“Proposal 1 - Election of eight directors to hold office until the Annual Meeting of Stockholders to be held in 2027 or until each such director’s respective successor is elected and qualified or until each such director’s earlier death, resignation or removal. Nominee FOR WITHHELD Broker Non-Votes Mark Comora, Chairman 246,057,694 4,493,592 6,406,353 Betsy L. Battle 247,691,808 2,859,478 6,406,353 Scott Dols 247,414,197 3,137,089 6,406,353 James Martell 247,466,228 3,085,058 6,406,353 Lance Moll 250,143,781 407,505 6,406,353 Nadeem Nisar 246,580,453 3,970,833 6,406,353 Scott Sutton 250,142,981 408,305 6,406,353 Ashok Vemuri 247,404,037 3,147,249 6,406,353”

Allogene Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-18 meeting.

“Proposal 5. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 282,022,884 503,156 198,378 0”

Allogene Therapeutics, Inc. shareholders approved Amendment to Amended and Restated Certificate of Incorporation To Increase the Number of Authorized Shares at the 2026-06-18 meeting.

“Proposal 4. Amendment to Amended and Restated Certificate of Incorporation To Increase the Number of Authorized Shares The Company’s stockholders approved an amendment (the "Amendment") to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 400,000,000 shares to 800,000,000. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 221,767,995 6,535,254 122,159 54,299,010”

Allogene Therapeutics, Inc. shareholders approved Approval, on an Advisory Basis, Say-On-Pay Vote Frequency at the 2026-06-18 meeting.

“Proposal 3. Approval, on an Advisory Basis, Say-On-Pay Vote Frequency The Company’s stockholders approved, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. The final voting results are as follows: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 224,054,368 228,313 757,992 3,384,735 54,299,010”

Allogene Therapeutics, Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers at the 2026-06-18 meeting.

“Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 213,098,167 11,951,256 3,375,985 54,299,010”

Allogene Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.

“Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Deborah Messemer 202,325,767 26,099,641 54,299,010 Vicki Sato, Ph.D. 202,326,299 26,099,109 54,299,010 Owen Witte, M.D. 189,310,484 39,114,924 54,299,010”

BridgeBio Oncology Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Accounting Firm at the 2026-06-16 meeting.

“Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm. The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions 34,535,875 3,440 0 There were zero broker non-votes and 13,805,126 no votes regarding this proposal.”

BridgeBio Oncology Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-16 meeting.

“Proposal 1 - Election of Directors. The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class I directors to hold office until the 2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. Director Nominee Votes For Votes Withheld Peter Lebowitz, M.D., Ph.D. 31,822,504 3,372 Frank P. McCormick, Ph.D., F.R.S., D. Sc. 25,654,119 6,171,757 There were 2,713,439 broker non-votes and 13,805,126 no votes regarding this proposal.”

CYPHERPUNK TECHNOLOGIES INC. shareholders approved Ratification of appointment of EisnerAmper LLP as independent registered public accounting firm at the 2026-06-18 meeting.

“The appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Votes For Votes Against Votes Abstaining 51,710,093 1,513,757 110,376”

CYPHERPUNK TECHNOLOGIES INC. shareholders approved Advisory vote on executive compensation of named executive officers at the 2026-06-18 meeting.

“The Company’s stockholders approved, on an advisory basis, the executive compensation of the Company’s named executive officers. Votes For Votes Against Votes Abstaining Broker Non-Votes 20,681,997 4,286,839 658,610 27,706,780”

CYPHERPUNK TECHNOLOGIES INC. shareholders approved Election of Class III directors at the 2026-06-18 meeting.

“The following director nominees were elected to serve as Class III directors until the Company’s 2029 annual meeting of stockholders and until their successors are duly elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes Will McEvoy 24,927,307 700,139 27,706,780 Nissim Mashiach 22,174,332 3,453,114 27,706,780”

STAAR SURGICAL CO shareholders approved To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers.

“Proposal 4 : To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers: Number of Shares For Against Abstain Broker Non-Votes 39,737,385 1,454,186 82,750 2,406,114”

STAAR SURGICAL CO shareholders approved To ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending January 1, 2027 at the 2027-01-01 meeting.

“Proposal 3 : To ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending January 1, 2027: Number of Shares For Against Abstain Broker Non-Votes 43,433,234 237,151 10,050 0”

STAAR SURGICAL CO shareholders approved To approve Amendment No. 2 to the Company’s Amended and Restated Omnibus Equity Incentive Plan, which increases the number of shares of Company common stock that are reserved for issuance under the plan by 3.9 million shares.

“Proposal 2: To approve Amendment No. 2 to the Company’s Amended and Restated Omnibus Equity Incentive Plan, which increases the number of shares of Company common stock that are reserved for issuance under the plan by 3.9 million shares: Number of Shares For Against Abstain Broker Non-Votes 40,231,475 974,989 67,857 2,406,114”

STAAR SURGICAL CO shareholders approved To elect seven directors to serve for a term of office expiring at the Company’s 2027 Annual Meeting of Shareholders or until their successors are duly elected and qualified.

“Proposal 1: To elect seven directors to serve for a term of office expiring at the Company’s 2027 Annual Meeting of Shareholders or until their successors are duly elected and qualified: Number of Shares For Withheld Broker Non-Votes Neal C. Bradsher 40,776,719 497,602 2,406,114 Arthur C. Butcher 40,565,567 708,754 2,406,114 Wei Jiang 41,098,173 176,148 2,406,114 Richard T. LeBuhn 41,170,957 103,364 2,406,114 Louis E. Silverman 40,487,195 787,126 2,406,114 Christopher M. Wang 40,941,468 332,853 2,406,114 Lilian Y. Zhou 40,488,276 786,045 2,406,114”

Oric Pharmaceuticals, Inc. shareholders approved Advisory Vote on the Frequency of Future Stockholder Advisory Votes on the Compensation of the Company’s Named Executive Officers at the 2026-06-18 meeting.

“Proposal 5 - Advisory Vote on the Frequency of Future Stockholder Advisory Votes on the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory (non-binding) basis, for the frequency of future stockholder advisory votes regarding executive compensation to be held every one year. In accordance with the recommendation of the Company’s board of directors and the voting results of the Company’s stockholders on this non-binding, advisory vote, the Company will hold an advisory (non-binding) vote on the compensation of the Company’s named executive officers on an annual basis. The next non-binding, advisory vote on the frequency of future stockholder advisory votes on the compensation of the Company’s named execute officers will take place no later than the Company’s annual meeting of stockholders in 2032. The tabulation of votes on this matter was as follows: For One Year For Two Years For Three Years Abstain Broker Non-Votes 89,392,979 6,9”

Oric Pharmaceuticals, Inc. shareholders approved Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2026-06-18 meeting.

“Proposal 4 - Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory (non-binding) basis, executive compensation. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 88,453,809 1,250,074 2,373 4,865,025”

Oric Pharmaceuticals, Inc. shareholders approved Approval of the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as Amended and Restated at the 2026-06-18 meeting.

“Proposal 3 - Approval of the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as Amended and Restated The Company’s stockholders approved the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as amended and restated. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 61,228,918 27,264,875 1,212,463 4,865,025”

Oric Pharmaceuticals, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-18 meeting.

“Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 94,536,096 34,641 544 0”

Oric Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.

“Proposal 1 - Election of Directors The Company’s stockholders elected each of the following nominees to serve as a Class III director, to hold office until the Company’s 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier death, resignation or removal. The tabulation of votes on this matter was as follows: Nominees For Withheld Broker Non-Votes Jacob M. Chacko, M.D. 89,298,150 408,106 4,865,025 Mardi C. Dier 82,007,899 7,698,357 4,865,025”

Pluri Inc. shareholders approved Ratification of the selection of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2026. at the 2026-06-15 meeting.

“Proposal No. 2 - Ratification of the selection of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2026. For Against Abstain Broker Non-Votes 7,558,826 20,364 2,007 N/A”